FGP
IOVA icon

Freestone Grove Partners’s Iovance Biotherapeutics IOVA Stock Holding History

Freestone Grove Partners’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$178K Buy
+42,858
New +$163K ﹤0.01% 809
2025
Q2 		– Sell
-15,480
Closed -$51.5K – 758
2025
Q1 		$51.5K Buy
+15,480
New +$79.8K ﹤0.01% 568

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Freestone Grove Partners's IOVA Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 42,858 shares worth $178K. The stake represents ﹤0.01% of the portfolio and ranks #809 among its holdings. This is a return to the name: Freestone Grove Partners previously reported a position in IOVA as recently as Q1 2025.

Freestone Grove Partners first reported a position in IOVA in Q1 2025 and has held it in 2 quarters since. 293 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • Freestone Grove Partners held 42,858 shares of Iovance Biotherapeutics worth $178K as of Q2 2026.
  • Iovance Biotherapeutics was a new Freestone Grove Partners position in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #809 holding.
  • Freestone Grove Partners first reported a position in Iovance Biotherapeutics in Q1 2025 and has held it in 2 quarters since.
  • 293 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.